2. Signaling Pathways
  3. GPCR/G Protein
  4. RXFP Receptor
  5. RXFP Receptor Activator

RXFP Receptor Activator

RXFP Receptor Activators (2):

Cat. No. Product Name Effect Purity
  • HY-P11625
    R9-13
    		Activator
    R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure.
  • HY-P992108
    Efadirelaxin alfa
    		Activator
    Efadirelaxin alfa (RELAX10) is a highly selective agonist of relaxin/insulin-like family peptide receptor RXFP1. After subcutaneous administration in animal experiments, Efadirelaxin alfa exhibits a significantly prolonged terminal half-life (7 days in mice, 3.75 days in rats), and shows no activity against related receptors such as RXFP2 and RXFP3. Efadirelaxin alfa has significant anti-cardiac hypertrophy and anti-fibrotic effects. Efadirelaxin alfa effectively attenuates and reverses cardiac hypertrophy and collagen deposition by regulating the TGF-β1/Smad2 and AKT/eNOS signaling pathways. Efadirelaxin alfa improves cardiac systolic function without causing fluctuations in blood pressure or heart rate, demonstrating favorable safety. Efadirelaxin alfa is currently mainly used in studies related to heart failure.